Date | Time | Source | Headline | Symbol | Company |
12/06/2009 | 17:53 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/06/2009 | 11:05 | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/06/2009 | 14:00 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/05/2009 | 13:00 | Business Wire | Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/05/2009 | 13:05 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/05/2009 | 13:00 | Business Wire | Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
14/05/2009 | 23:15 | Business Wire | Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
12/05/2009 | 13:00 | Business Wire | Allos Therapeutics to Present at the Eighth Annual JMP Securities Research Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/05/2009 | 22:01 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/05/2009 | 21:06 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/05/2009 | 21:00 | Business Wire | Allos Therapeutics Reports First Quarter 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
30/04/2009 | 13:31 | Edgar (US Regulatory) | Amended Annual Report (10-K/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/04/2009 | 21:00 | Business Wire | Allos Therapeutics to Report First Quarter 2009 Results on May 5, 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/04/2009 | 12:54 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
19/04/2009 | 20:00 | Business Wire | Allos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
15/04/2009 | 13:00 | Business Wire | Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/04/2009 | 21:05 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
03/04/2009 | 21:00 | Business Wire | Allos Therapeutics Announces Closing of Common Stock Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/04/2009 | 21:14 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/04/2009 | 21:10 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(5) (424B5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
31/03/2009 | 14:06 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
31/03/2009 | 14:00 | Business Wire | Allos Therapeutics Announces Pricing of Common Stock Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
27/03/2009 | 21:35 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
26/03/2009 | 12:00 | Business Wire | Allos Therapeutics to Present at the 4th Annual Citi Biotech Day | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
25/03/2009 | 12:06 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
25/03/2009 | 12:00 | Business Wire | Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell L... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/03/2009 | 21:30 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/03/2009 | 12:06 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
24/03/2009 | 12:00 | Business Wire | Allos Therapeutics Appoints David M. Stout to Its Board of Directors | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/03/2009 | 20:58 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |